Risk lower for men with newly diagnosed prostate cancer on active surveillance protocol<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
THURSDAY, Jan. 21, 2021 (HealthDay News) — For men with newly diagnosed prostate cancer on active surveillance, adherence to the Mediterranean diet (MedD) is associated with a lower risk for Gleason grade group progression, according to a study published online Jan. 7 in Cancer<\/em>.<\/p>\n Justin R. Gregg, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues examined adherence to the MedD and Gleason score progression in a cohort of 410 men with newly diagnosed prostate cancer on an active surveillance protocol. Participants completed a baseline food frequency questionnaire, and the MedD score was calculated across nine energy-adjusted food groups.<\/p>\n The researchers found that 76 men progressed during a median follow-up of 36 months. Higher adherence to the MedD correlated with a lower risk for Gleason grade group progression after adjustment for clinical factors among all men (hazard ratio [HR] per one-unit increase in MedD score, 0.88; 95 percent confidence interval [CI], 0.77 to 1.01), non-White men (HR, 0.64; 95 percent CI, 0.45 to 0.92; P for interaction = 0.07), and men without diabetes (HR, 0.82; 95 percent CI, 0.71 to 0.96; P for interaction = 0.03). The risk reduction was similar among men with high MedD scores who did not use statins compared with men with low\/moderate MedD scores with no statin use.<\/p>\n “Our findings suggest that consistently following a diet rich in plant foods, fish, and a healthy balance of monounsaturated fats may be beneficial for men diagnosed with early-stage prostate cancer,” Gregg said in a statement.<\/p>\n One author disclosed financial ties to the biopharmaceutical and medical device industries.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n